This is a revised competing continuation application for R01 AI055359-02, DOT-HAART for HIV-infected South African Adults. We are seeking two additional years of funding (5 years total) to complete our trial and attain primary endpoints on all patients. The primary objective of this study is to evaluate the effectiveness and feasibility of directly observed therapy (DOT) using patient-nominated peer supervisors as a strategy to improve adherence to highly active antiretroviral therapy (HAART) in HIV-infected adults in South Africa. Recent international initiatives provide hope for widespread use of HAART in sub-Saharan Africa. However, feasibility, long-term adherence and effective delivery of HAART remain formidable barriers. Peer advocates providing social support and oversight have been used to improve adherence with medical therapies in a variety of settings. We are investigating the utility of Peer-DOT-HAART regimens in South Africa in a randomized trial in which patients are randomized to either Peer-DOT-HAART or self-administration of antiretrovirals for 24 months.
The specific aims of this study are: 1) to evaluate the impact of Peer-DOT- HAART on CD4 cell counts and HIV viral load; 2) to evaluate the impact of DOT-HAART on treatment adherence; 3) to determine the frequency of genotypic resistance to HAART during treatment; and 4) to compare incidence of new or recurrent opportunistic infection in both arms. We hypothesize that the patients on the DOT-HAART regimen will have higher levels of treatment adherence and more effective control of viral burden, thereby reducing virologic failure, drug resistance and disease progression. To date, we have enrolled 200 patients into the trial and anticipate reaching full enrollment in late 2006. We will have the preliminary endpoints (1-year viral load and CD4 cell count change) available for all patients in late 2007 and final results in early 2009. This revision provides further details on progress to date and reasons for the delay in starting the trial. This study will generate critical data on an alternative community-based approach of delivering HAART which may become a standard of care applicable throughout sub-Saharan Africa and the whole developing world. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI055359-05
Application #
7395040
Study Section
Behavioral and Social Consequences of HIV/AIDS Study Section (BSCH)
Program Officer
Livnat, Daniella
Project Start
2003-04-01
Project End
2010-03-31
Budget Start
2008-04-01
Budget End
2010-03-31
Support Year
5
Fiscal Year
2008
Total Cost
$514,599
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Hoffmann, Christopher J; Lewis, James J; Dowdy, David W et al. (2013) Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model. J Acquir Immune Defic Syndr 63:105-11
Hoffmann, Christopher J; Ledwaba, Johanna; Li, Jin-Fen et al. (2013) Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa. Antivir Ther 18:915-20
Duwell, Monique M; Knowlton, Amy R; Nachega, Jean B et al. (2013) Patient-nominated, community-based HIV treatment supporters: patient perspectives, feasibility, challenges, and factors for success in HIV-infected South African adults. AIDS Patient Care STDS 27:96-102
Svensson, Elin; van der Walt, Jan-Stefan; Barnes, Karen I et al. (2012) Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. Br J Clin Pharmacol 74:465-76
Nachega, Jean B; Morroni, Chelsea; Chaisson, Richard E et al. (2012) Impact of immune reconstitution inflammatory syndrome on antiretroviral therapy adherence. Patient Prefer Adherence 6:887-91
Hoffmann, Christopher J; Fielding, Katherine L; Johnston, Victoria et al. (2011) Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr 58:269-76
Hoffmann, Christopher J; Fielding, Katherine L; Charalambous, Salome et al. (2010) Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. AIDS 24:1709-16
Nachega, Jean B; Leisegang, Rory; Bishai, David et al. (2010) Association of antiretroviral therapy adherence and health care costs. Ann Intern Med 152:18-25
Charalambous, Salome; Grant, Alison D; Innes, Craig et al. (2010) Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 24 Suppl 5:S5-13
Nachega, Jean B; Chaisson, Richard E; Goliath, Rene et al. (2010) Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS 24:1273-80

Showing the most recent 10 out of 22 publications